ShareValue scores for FEMY: Valuation 47, Quality 21, Growth 53, Health 65.

FEMY
NASDAQ

Femasys Inc

$2.95(-1.99%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
47
Fair Value
Price vs Value
Quality
21
Weak
Business Strength
Growth
53
Moderate
Revenue & Earnings
Health
65
Moderate
Financial Stability
Momentum
11
Bearish
Price Trend

Company Details

About

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026